Abstract: The present invention relates to a shoe sole, in particular for a sports shoe, where the sole includes a cartridge cushioning system that includes a load distribution plate arranged in a heel region of the shoe sole, at least one cushioning element for determining the cushioning properties of the shoe sole during the first ground contact with the heel, and at least one guidance element to guide the foot into a neutral position after the first ground contact.

Abstract: This invention relates to fluorophenyl-substituted alkenylcarboxylic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament containing them.

Abstract: Compact and preferably cellular polyurethane elastomers based on polyisocyanate mixtures containing 3,3′-dimethylbiphenyl 4,4′-diisocyanate are produced by reacting a) relatively high molecular weight polyhydroxyl compounds and, if desired, b) low molecular weight hydroxyl-containing chain extenders and/or crosslinkers with c) 3,3′-dimethylbiphenyl 4,4′-diisocyanate and at least one additional aromatic diisocyanate selected from the group consisting of tolylene diisocyanate, diphenylmethane diisocyanate, 1,2-diphenylethane diisocyanate and phenylene diisocyanate, and/or at least one aliphatic diisocyanate having from 4 to 12 carbon atoms and/or at least one cycloaliphatic diisocyanate having from 6 to 18 carbon atoms, where the formative components (a), (c) and, if used, (b) are advantageously reacted by the prepolymer method, in the presence or absence of d) catalysts, e) blowing agents and f) additives.

Abstract: Diacyl-substituted guanidines of the formula I are described where X(1) and X(2) are as defined herein. The compounds are suitable for use as antiarrhythmic pharmaceuticals possessing a cardioprotective component for the prophylaxis and treatment of infarction and for the treatment of angina pectoris, in connection with which they also inhibit or strongly reduce, in a preventitive manner the pathophysiological processes associated with the genesis of ischemically induced damage, in particular associated with the elicitation of ischemically induced cardiac arrhythmias.

Abstract: The present invention relates to athletic shoes used in sports that require asymmetric movement of the feet, such as fencing. The asymmetric shoes of the present invention include a trailing shoe and a leading shoe that are each specially adapted to the particular asymmetric movement of the trailing and leading foot, respectively, allowing each foot to perform optimally. The leading and trailing shoes each include an upper and a sole. The trailing shoe sole includes front, rear, lateral, and medial portions, the lateral sole portion having a greater thickness than the medial portion.

Abstract: A critical care workstation includes a display device and a processor, coupled to the display device. The processor executes both a general purpose operating system controlling execution of a selected program for displaying images representing non-real-time data on the display device, and a real-time kernel, controlling execution of a program for displaying images representing real-time data on the display device simultaneously with the display of the non-real-time data. In addition circuitry, responsive to user input, selects a non-real-time display program to execute under the control of the general purpose operating system from among a plurality of available non-real-time display programs.

Abstract: Pharmaceutical combination preparation of an inhibitor of the sodium/hydrogen exchanger and a medicament for the treatment of cardiovascular diseases. These combinations of an NHE inhibitor can comprise one or more therapeutically active compounds having cardiovascular activity. The combination of the cardioprotective properties with known therapies of cardiovascular diseases leads on the one hand to an improvement of the quality of the treatment and on the other hand in a large number of combinations to an additive or potentiated increase of the cardiovascular effects of the individual active compounds alone.

Abstract: The present invention relates to athletic shoes used in sports that require asymmetric movement of the feet, such as fencing. The asymmetric shoes of the present invention include a trailing shoe and a leading shoe that are each specially adapted to the particular asymmetric movement of the trailing and leading foot, respectively, allowing each foot to perform optimally. The leading and trailing shoes each include an upper and a sole. The trailing shoe sole includes front, rear, lateral, and medial portions, the lateral sole portion having a greater thickness than the medial portion.

Abstract: Compact and preferably cellular polyurethane elastomers are produced by reacting a) polyhydroxyl compounds having molecular weights of from 800 to 6000 and, if desired, b) chain extenders and/or crosslinkers having molecular weights of up to 800 [lacuna] c) naphthylene 1,5-diisocyanate and at least one additional aromatic diisocyanate selected from the group consisting of tolylene diisocyanate, diphenylmethane diisocyanate, 3,3′-dimethylbiphenyl diisocyanate, 1,2-diphenylethane diisocyanate and phenylene diisocyanate, and/or aliphatic diisocyanate having from 4 to 12 carbon atoms and/or cycloaliphatic diisocyanate having from 6 to 18 carbon atoms, where the formative components (a), (c) and, if used, (b) are preferably reacted by the prepolymer method, in the presence or absence of d) catalysts, e) blowing agents and f) additives. Isocyanate prepolymers suitable for this purpose are also described.

Abstract: This invention relates to fluorophenyl-substituted alkenylcarboxylic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament containing them.

Abstract: Ortho-substituted benzoylguanidines of the formula I in which R(1) to R(4) have the meanings given in the claims, are suitable, as antiarrhythmic pharmaceuticals having a cardioprotective component, for the prophylaxis and treatment of infarction and for the treatment of angina pectoris. They also inhibit, in a preventive manner, the pathophysiological processes associated with the genesis of ischemically induced damage, in particular associated with the triggering of ischemically induced cardiac arrhythmias.

Abstract: Patient monitoring apparatus for use in an environment which includes a plurality of sensors. The apparatus provides collection and display of patient data signals collected from a medical patient using the sensors, including periods when the patient is being transported. The apparatus comprises a portable monitor coupled to a plurality of distinct data acquisition modules, which are coupled to the sensors. The modules includes cartridges, which detachably mount to the portable monitor, and pods which are positioned independent of the monitor. The pods reduce the number of cables extending between the patient's bed and the portable monitor by combining signals from many sensors into a single output signal. The modules collect patient data in analog form from the sensors and provide digital data signals to the monitor. The portable monitor includes: a display device for displaying the patient data, and storage for the patient data. The portable monitor may be coupled to a docking station.

Abstract: Compact and preferably cellular polyurethane elastomers are prepared by reacting a) relatively high molecular weight polyhydroxyl compounds and if desired, b) low molecular weight chain extenders and/or crosslinkers with c) phenylene 1,4-diisocyanate (p-PDI) and at least one additional aromatic diisocyanate selected from the group consisting of tolylene diisocyanate, diphenylmethane diisocyanate, 3,3′-dimethylbiphenyl diisocyanate, 1,2-diphenylethane diisocyanate and/or aliphatic diisocyanate, having from 4 to 12 carbon atoms and/or cycloaliphatic diisocyanate having from 6 to 18 carbon atoms, where the formative components (a), (c) and, if used, (b) are advantageously reacted by the prepolymer method, in the presence or absence of d) catalysts, e) blowing agents and f) additives. Isocyanate prepolymers suitable for this purpose are described.

Abstract: There are described benzoylguanidines of the formula I ##STR1## where R(1) is R(4)--SO.sub.m, R(5)R(6)N--SO.sub.2 --; O.sub.p --(CH.sub.2).sub.q --(CF.sub.2).sub.r --CF.sub.3 ; --SR(10), --OR(10) or --CR(10)R(11)R(12); R(2) is --(CH.sub.2).sub.u --(CF.sub.2).sub.t --CF.sub.3 ; R(3) is hydrogen or independently defined as R(1); and their pharmaceutically tolerable salts. They are obtained by reaction of a compound of the formula II ##STR2## with guanidine. They are compounds of outstanding activity on the cardiovascular system.

Abstract: Ortho-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them.Ortho-substituted benzoylguanidines of the formula I ##STR1## in which R(1) to R(4) have the meanings given in the claims, are suitable, as antiarrhythmic pharmaceuticals having a cardioprotective component, for the prophylaxis and treatment of infarction and for the treatment of angina pectoris. They also inhibit, in a preventive manner, the pathophysiological processes associated with the genesis of ischemically induced damage, in particular associated with the triggering of ischemically induced cardiac arrhythmias.

Abstract: Substituted bicyclic heteroaroylguanidines, a process for their preparation, their use as a medicament or a diagnostic agent, and a medicament containing them are described, as are the pharmaceutically tolerated salts thereof. A process for their preparation, and their use as medicines and diagnostic aids in cardiovascular diseases, is also described.

Abstract: Benzoylguanidines of formula I ##STR1## with R(1) to R(4) as defined in the specification, are suitable as antiarrhythmic pharmaceuticals having a cardioprotective component for infarct prophylaxis and infarct treatment as well as for the treatment of angina pectoris.They inhibit, in a preventive manner, the pathophysiological processes in the formation of ischemically induced damage, in particular in the elicitation of ischemically induced cardiac arrhythmias.

Abstract: A microcellular PU elastomer having improved dynamic-mechanical properties and based on an isocyanate component consisting essentially of 4,4'-MDI and also further customary constituents has, after heating at from 100 to 120.degree. C. for from 8 to 24 hours, a melting range of from 130.degree. C. as the minimum lower limit to 230.degree. C. as a minimum upper limit, measured by differential scanning calorimetry (DSC) at a heating rate of 20.degree. C./min, and a urea content of from 14 to 18% by weight.A process is also provided for preparing such a microcellular PU elastomer having improved dynamic mechanical properties. The microcellular PU elastomers can be used for producing damping elements.

Abstract: Compounds of the formula I ##STR1## and the pharmaceutically tolerated salts thereof, are described. A process for their preparation and their use as medicaments in cardiovascular diseases are also described.

Abstract: A microcellular PU elastomer having improved dynamic mechanical properties and based on an isocyanate component consisting essentially of 4,4'-MDI and further customary constituents has a physicochemical structure which, in the gel permeation chromatograph (GPC) of a solution of the microcellular polyurethane elastomer prepared at 90.degree. C. in N,N-dimethylformamide containing 1 percent of di-n-butylamine measured against polymethyl methacrylate (PMMA) as standard, displays a signal occurring in addition to low molecular weight main signal and comprising one or more peaks at an (apparent) molar mass of greater than 250,000 g/mol which becomes smaller or disappears on addition of lithium chloride to this solution, and a urea content of from 14 to 18% by weight.A process is also provided for preparing such a microcellular PU elastomer having improved dynamic mechanical properties. The microcellular PU elastomers can be used for producing damping elements.